Angiogenesis in diabetes and obesity

Cheng, Rui; Xing, Jian

doi:10.1007/s11154-015-9310-7

Cited by 96 publications

(70 citation statements)

References 151 publications

(151 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Persistent, uncontrolled angiogenesis is a key pathological characteristic of the microvascular complications of DM [6]. Moreover, in DM, there are two tissue specific paradoxical events in the vasculature with excessive formation of premature blood vessels afflicting the retina, while deficiency of small blood vessels in the skin, contributes to impaired wound healing [6]. Hence, the use of angiogenic inhibitors is a common treatment modality for diabetic retinopathy [27, 28].…”

Section: Discussionmentioning

confidence: 99%

“…The pathogenesis of TB-DM co-morbidity is not completely understood, but chronic inflammation appears to be the central underlying pathogenic feature [4, 5]. In addition, dysregulated angiogenesis also appears to be a major characteristic of TB and DM independently [6, 7]. Angiogenesis is typically regulated by the vascular endothelial growth family members, which includes VEGF-A, VEGF-B, VEGF-C and VEGF-D [8].…”

Section: Introductionmentioning

confidence: 99%

“…It has also been reported that interference with angiogenic or lymphangiogenic pathways in experimental models of mycobacterial infection results in significantly improved treatment outcomes as well as diminished mycobacterial growth [16, 17]. In addition, angiogenesis plays a prominent role in the pathogenesis of DM and its complications [6]. A paradoxical feature of DM pathogenesis appears to be that vascular impairment (or diminished angiogenesis) and excessive angiogenesis can co-exist in different organs of the same host [18].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors

Kumar

Moideen

Shanmugam

et al. 2017

Journal of Infection

View full text Add to dashboard Cite

Background Tuberculosis-diabetes co-morbidity (TB-DM) is characterized by increased inflammation with elevated circulating levels of inflammatory cytokines and other factors. Circulating angiogenic factors are intricately involved in the angiogenesis-inflammation nexus. Methods To study the association of angiogenic factors with TB-DM, we examined the systemic levels of VEGF-A, VEGF-C, VEGF-D, VEGF-R1, VEGF-R2, VEGF-R3 in individuals with either TB-DM (n=44) or TB alone (n=44). Results Circulating levels of VEGF-A, C, D, R1, R2 and R3 were significantly higher in TB-DM compared to TB individuals. Moreover, the levels of VEGF-A, C, R2 and/or R3 were significantly higher in TB-DM with bilateral or cavitary disease or with hemoptysis, suggesing an association with both disease severity and adverse clinical presentation. The levels of these factors also exhibited a significant positive relationship with bacterial burdens and HbA1c levels. In addition, VEGF-A, C and R2 levels were signifantly higher (at 2 months of treatment) in culture positive compared to culture negative TB-DM individuals. Finally, the circulating levels of VEGF-A, C, D, R1, R2 and R3 were significantly reduced following successful chemotherapy at 6 months. Conclusion Our data demonstrate that TB-DM is associated with heightened levels of circulating angiogenic factors, possibly reflecting both dysregulated angiogenesis and exaggerated inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors

Kumar

Moideen

Shanmugam

et al. 2017

Journal of Infection

View full text Add to dashboard Cite

show abstract

“…They based this assumption on a correlation they found between fasting oGTT glucose values and first-trimester PlGF concentration. It is well established that hyperglycemia affects angiogenesis [19]. In diabetic retinopathy VEGF is upregulated, while decreased VEGF levels contribute to impaired wound healing in diabetes [19].…”

Section: Discussionmentioning

confidence: 99%

“…It is well established that hyperglycemia affects angiogenesis [19]. In diabetic retinopathy VEGF is upregulated, while decreased VEGF levels contribute to impaired wound healing in diabetes [19]. Vasculogenesis and angiogenesis are essential for placental development and the VEGF family has been shown to play a key role [20].…”

Section: Discussionmentioning

confidence: 99%

First-Trimester Placental Growth Factor in Screening for Gestational Diabetes

Mosimann¹,

Amylidi²,

Risch

et al. 2015

Fetal Diagn Ther

View full text Add to dashboard Cite

Objective: The aim of this study was first to assess whether first-trimester serum concentrations of placental growth factor (PlGF) differ between patients with and without gestational diabetes (GDM) and second to test whether there is a correlation between glycosylated hemoglobin (HbA1c), a factor recently shown to be useful in predicting GDM, and PlGF. Methods: PlGF was measured at 8-14 weeks with the Kryptor Immunoassay Analyzer (Brahms, Berlin, Germany). Absolute values were converted to multiples of the median using the software provided by the Fetal Medicine Foundation London. GDM was diagnosed using internationally accepted criteria. HbA1c levels were quantified using the TOSOH G7 automated hemoglobin analyzer. Results: From January to December 2014, 328 women were included in the study, 51 (15.5%) of whom developed GDM. First-trimester PlGF quantification does not discriminate between women at risk to develop GDM and controls, while HbA1c is able to do so. No correlation was found between PlGF and HbA1c. Conclusion: Our findings do not lend support to the hypothesis that early PlGF values are different in women who later develop GDM.

show abstract

Molecular evidence of field cancerization initiated by diabetes in colon cancer patients

et al. 2019

View full text Add to dashboard Cite

The potential involvement of type 2 diabetes mellitus (T2 DM ) as a risk factor for colon cancer ( CC ) has been previously reported. While several clinical studies show a higher incidence of CC and a lower survival rate in diabetics, others report no association. Our own experience indicates that diabetes does not seem to worsen the prognosis once the tumor is present. Despite this controversy, there are no wide‐spectrum molecular studies that delve into the impact of T2 DM ‐related mechanisms in colon carcinogenesis. Here, we present a transcriptomic and proteomic profiling of paired tumor and normal colon mucosa samples in a cohort of 42 CC patients, 23 of which have T2 DM . We used gene set enrichment and network approaches to extract relevant pathways in diabetics, referenced them to current knowledge, and tested them using in vitro techniques. Through our transcriptomics approach, we identified an unexpected overlap of pathways overrepresented in diabetics compared to nondiabetics, in both tumor and normal mucosa, including diabetes‐related metabolic and signaling processes. Proteomic approaches highlighted several cancer‐related signaling routes in diabetics found only in normal mucosa, not in tumors. An integration of the transcriptome and proteome analyses suggested the deregulation of key pathways related to colon carcinogenesis which converged on tumor initiation axis TEAD / YAP ‐ TAZ as a potential initiator of the process. In vitro studies confirmed upregulation of this pathway in nontumor colon cells under high‐glucose conditions. In conclusion, T2 DM associates with deregulation of cancer‐related processes in normal colon mucosa adjacent to tissue which has undergone a malignant transformation. These data support that in diabetic patients, the local microenvironment in normal colon mucosa may be a factor driving field cancerization promoting carcinogenesis. Our results set a new framework to study links between diabetes and colon cancer, including a new role of the TEAD / YAP ‐ TAZ complex as a potential driver.

show abstract

Angiogenesis in diabetes and obesity

Cited by 96 publications

References 151 publications

Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors

Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors

First-Trimester Placental Growth Factor in Screening for Gestational Diabetes

Molecular evidence of field cancerization initiated by diabetes in colon cancer patients

Contact Info

Product

Resources

About